Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $277.0M |
| Sales growthchange from the year before | +54.8% |
| Gross marginshare of sales left after the direct cost of what it sells | 74.2% |
| Operating marginshare of sales left after running the business | -20.6% |
| Net marginshare of sales kept as profit | -21.5% |
| Free-cash-flow marginspare cash generated per $100 of sales | -17.7% |
| Return on invested capitalprofit made on each $100 put into the business | -12.9% |
| Return on equityprofit vs. shareholders' accounting value | -27.2% |
| Debt / equitydebt vs. shareholders' accounting value | 0.60 |
| Interest coverhow many times profit covers interest payments | -4.8x |
| Change in share countnegative = the company is buying back its shares | +3.1% |
2 insiders sold $10.8M (all under pre-arranged plans) on the open market.
| Bobulsky SusanChief Commercial Officer, MRD | Sold (plan)Jul 30 | 1,299 shat $24.00 · $31K |
| Robins Harlan SChief Scientific Officer | Sold (plan)Jul 21 | 492,400 shat $21.89 · $10.8M |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy